XML 161 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2024
Schedule of common stock issued roll forward

 

Year Ended December 31,

2024

2023

2022

Common stock:

Balance, beginning of period

183,606,708

171,656,030

155,516,284

Shares issued for stock options exercised

380,919

832,993

2,105,237

Agent growth incentive stock compensation

1,787,280

2,219,881

2,571,569

Agent equity stock compensation

9,253,300

8,897,804

11,462,940

Balance, end of period

195,028,207

183,606,708

171,656,030

Schedule of Restricted stock activity

The following table illustrates the Company’s stock activity for the Agent Growth Incentive Program for stock awards where the performance metric has been achieved for the following periods:

Weighted Average

Grant Date

    

Shares

    

Fair Value

Balance, December 31, 2022

5,698,997

$ 17.68

Granted

4,642,035

15.04

Vested and issued

(2,219,881)

11.73

Forfeited

(1,245,862)

17.35

Balance, December 31, 2023

6,875,289

$ 17.80

Granted

4,588,562

12.22

Vested and issued

(1,787,280)

22.99

Forfeited

(1,720,193)

15.93

Balance, December 31, 2024

7,956,378

$13.80

Schedule of stock options fair value assumptions

2024

2023

2022

Expected term

5 years

5 - 6 years

5 - 6 years

Expected volatility

73.51% - 74.29%

73.64% - 76.78%

72.84% - 76.49%

Risk-free interest rate

3.48% - 4.61%

3.28% - 4.86%

1.49% - 4.10%

Dividend yield

1.39% - 1.99%

0.72% - 1.64%

0.53% - 1.48%

Schedule of stock option activity

Weighted

Average

Weighted

Remaining

Average

Contractual Term

    

Options

    

Exercise Price

    

Intrinsic Value

    

(Years)

Balance December 31, 2022

5,774,522

$ 13.56

$ 2.21

7.63

Granted

2,468,299

14.81

-

8.46

Exercised

(832,993)

5.90

14.97

 —

Forfeited

(1,198,706)

17.77

2.27

 —

Expired

(12,578)

35.54

0.29

 —

Balance at December 31, 2023

6,198,544

$ 14.23

$ 3.62

7.29

Granted

1,012,111

11.74

-

9.19

Exercised

(380,919)

5.29

5.79

 —

Forfeited

(959,539)

18.84

0.05

 —

Expired

(300,052)

23.60

0.04

 —

Balance at December 31, 2024

5,570,145

$ 13.09

$ 1.17

6.97

Exercisable at December 31, 2024

3,380,785

$ 12.51

$ 1.83

5.86

Vested at December 31, 2024

3,380,785

$ 12.51

$ 1.83

5.86

Weighted

Average

Options

    

Exercise Price

Range of stock option exercise prices at December 31, 2024:

$0.01 - $10.00 (average remaining life - 5.08 years)

2,215,601

$ 8.74

$10.01 - $30.00 (average remaining life - 8.35 years)

3,112,541

$ 14.23

$30.01 - $60.00 (average remaining life - 6.39 years)

242,003

$ 38.37

Schedule of shares repurchased

Year Ended December 31,

2024

2023

2022

Treasury stock:

Balance, beginning of period

28,937,671

18,816,791

6,751,692

Repurchases of common stock

11,957,151

10,110,152

12,408,430

Forfeiture to treasury stock for acquisition

-

10,728

-

Issuance of treasury stock for acquisition

-

-

(343,331)

Balance, end of period

40,894,822

28,937,671

18,816,791

Agent Growth Incentive Program  
Changes in the Company's stock compensation liability

The following table illustrates changes in the Company’s stock compensation liability, included in accrued liabilities for the periods presented:

Amount

Stock grant liability balance at December 31, 2022

$ 3,885

Stock grant liability increase year to date

3,832

Stock grants reclassified from liability to equity year to date

(2,717)

Balance, December 31, 2023

$ 5,000

Stock grant liability increase year to date

2,251

Stock grants reclassified from liability to equity year to date

(2,206)

Balance, December 31, 2024

$ 5,045